I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

IMS 2026

We will be contributing to topics related to
-
12:00 PM
Duration 240mins Glasgow, Scotland
CEVOLUTION: A randomized phase III trial comparing cevostamab plus pomalidomide and dexamethasone (pom-dex) versus standard of care (SOC) in relapsed/refractory multiple myeloma (RRMM)
Rakesh Popat, Adam Cohen, Amrita Krishnan, Divya Samineni, Elena Zamagni, Hira S. Mian, Joshua Richter, Kerstin Trunzer, Tulika Tyagi, Leanne Richardson, Paresh Sewpaul,, Sammy Chebon, Tina Nielsen, Binod Dhakal
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:30 PM
Duration 12mins Glasgow, Scotland
A fixed-duration, modified cevostamab dosing regimen induces durable remissions that continue after completion in BCMA-naïve pts with relapsed/refractory multiple myeloma (RRMM): CAMMA 1 Arm A results
Ameet Mishra, Amrita Krishnan, Divya Samineni, Henning Schade, Leanne Richardson, Ravi Vij, Sammy Chebon, Simon Harrison, Suzanne Trudel, Tulika Tyagi, Vanessa Grassi
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 12mins Glasgow, Scotland
Cevostamab plus pomalidomide (pom) and dexamethasone (dex) induces durable remissions in BCMA-naïve patients with relapsed/refractory multiple myeloma (RRMM): CAMMA 1 Arm B extended follow-up data
Andrew Spencer, Hira S Mian, Kihyun Kim, Laura Paris, Rakesh Popat, Simon J Harrison, Anna Caroline Hasselbalch, Noa Lavi, Tomas Jelinek, Monika Szarejko, Sebastian Grosicki, Irwindeep Sandhu, Vanessa Grassi, Tulika Tyagi, Paresh Sewpaul, Leanne Richardson, Ameet Mishra, Suzanne Trudel
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:30 AM
Duration 50mins Glasgow, Scotland
Cevostamab: A FcRH5xCD3 bispecific antibody for the treatment of multiple myeloma
Paresh Sewpaul
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon